{"DataElement":{"publicId":"2217968","version":"1","preferredName":"Patient Warfarin Treatment Ind-2","preferredDefinition":"the yes/no indicator that asks whether the patient is receiving a stable dose of warfarin and has an in-range INR or receiving a stable dose of heparin.","longName":"PT_WARF_TX_IND2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2217967","version":"1","preferredName":"Patient Warfarin Treatment","preferredDefinition":"information relating to patient warfarin treatment.","longName":"PATIENT_WARF_TREAT","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177068","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"Patient","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AB6-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2217965","version":"1","preferredName":"Warfarin Therapy","preferredDefinition":"An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C0043031:C15368","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Warfarin","conceptCode":"C0043031","definition":"An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F428C665-7664-2F56-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-08","modifiedBy":"ONEDATA","dateModified":"2005-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F428C665-7666-2F56-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811954","version":"1","longName":"Eligibility Criteria","context":"CTEP"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000172","version":"1","longName":"GOG-0241","context":"NRG"},{"publicId":"4104913","version":"1","longName":"GOG-0241","context":"NRG"},{"publicId":"4104881","version":"1","longName":"GOG-0227G","context":"NRG"},{"publicId":"10000346","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000345","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104907","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104892","version":"1","longName":"GOG-0229O","context":"NRG"},{"publicId":"4104916","version":"1","longName":"GOG-0257","context":"NRG"},{"publicId":"10000500","version":"1","longName":"GOG-0257","context":"NRG"},{"publicId":"10000499","version":"1","longName":"GOG-0257","context":"NRG"}]}],"AlternateNames":[{"name":"SWOG","type":"USED_BY","context":"SWOG"},{"name":"WARFAR","type":"OID, SWOG","context":"SWOG"},{"name":"PT_WARF_TX_IND2","type":"USED_BY","context":"Alliance"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"PT_WARF_TX_IND2","type":"USED_BY","context":"NRG"},{"name":"PT_WARF_TX_IND2","type":"USED_BY","context":"CITN"}],"ReferenceDocuments":[{"name":"Is the patient receiving a st","type":"Preferred Question Text","description":"Is the patient receiving a stable dose of warfarin and has an in-range INR or receiving a stable dose of heparin","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Is the patient having ongoing treatment with therapeutic doses of warfarin?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Does the patient require therapeutic doses of coumadin or equivalent?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Is the patient taking warfarin?","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Receiving therapeutic anticoagulation with Warfarin","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Is patient on warfarin?","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Is the patient currently receiving or has received warfarin or acenocoumarol within the past 7 days?","url":null,"context":"CTEP"},{"name":"CRF Text7","type":"Alternate Question Text","description":"Does the patient require concomitant treatment, in therapeutic doses, with anti-coagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors or antiplatelet agents (i.e. clopidogrel)?","url":null,"context":"CTEP"},{"name":"Has patient received therapeutic dose of warfarin?","type":"Alternate Question Text","description":"Has patient received therapeutic dose of warfarin?","url":null,"context":"SWOG"},{"name":"CRF TEXT 4","type":"Alternate Question Text","description":"Low-dose Coumadin (1mg) is acceptable; however, doses that increase the INR are not permitted. If an alternative to Coumadin-based anticoagulants cannot be used, the INR should be monitored weekly after initiation of therapy and upon discontinuation of INCB024360, until INR normalization.","url":null,"context":"CTEP"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"Is the patient on Coumadin?","url":null,"context":"NRG"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Are they on a stable dose and have no underlying abnormality in coagulation parameters per medical history?","url":null,"context":"CTEP"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"Is the patient therapeutically treated with an agent such as warfarin?","url":null,"context":"CTEP"},{"name":"CRF Text 10","type":"Alternate Question Text","description":"Is the patient therapeutically treated with an agent such as warfarin or heparin?","url":null,"context":"NRG"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F440E238-2483-4881-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-08","modifiedBy":"SARAHB","dateModified":"2022-03-28","changeDescription":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}